Joel Isaacson & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Joel Isaacson & Co’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,000	Closed	-$45K	–	583
2016 Q4	$45K	Hold	2,000	–	–	0.01%	325
2016 Q3	$45K	Hold	2,000	–	–	0.01%	340
2016 Q2	$47K	Hold	2,000	–	–	0.01%	332
2016 Q1	$41K	Hold	2,000	–	–	0.01%	362
2015 Q4	$103K	Hold	2,000	–	–	0.03%	226
2015 Q3	$85K	Hold	2,000	–	–	0.02%	252
2015 Q2	$91K	Hold	2,000	–	–	0.02%	268
2015 Q1	$76K	Hold	2,000	–	–	0.02%	300
2014 Q4	$57K	Hold	2,000	–	–	0.02%	310
2014 Q3	$51K	Hold	2,000	–	–	0.02%	302
2014 Q2	$58K	Hold	2,000	–	–	0.02%	287
2014 Q1	$52K	Hold	2,000	–	–	0.02%	292
2013 Q4	$52K	Buy	+2,000	New	+$48.6K	0.02%	264

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Joel Isaacson & Co's PTLA Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2017, closing a stake of 2,000 shares — an estimated $45K sold.

Joel Isaacson & Co first reported a position in PTLA in Q4 2013 and held it in 13 quarters. The position peaked at $103K in Q4 2015. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2017.

Joel Isaacson & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 2,000 Portola Pharmaceuticals, Inc. shares in Q1 2017, an estimated $45K.
Joel Isaacson & Co first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 13 quarters.
Joel Isaacson & Co's Portola Pharmaceuticals, Inc. position peaked at $103K in Q4 2015.
180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.